NR1I3

Across TCGA pan-cancer cohorts, NR1I3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NR1I3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NR1I3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NR1I3 expression acts as an unfavorable survival marker.

LUAD, CESC, and HNSC are the cancer types where NR1I3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.171	0.681	<.001	31	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	24	view →
HNSC	OS	Median	II,III,IV	0.069	0.757	<.001	12	view →
COAD	OS	Median	II,III,IV	0.111	0.853	<.001	12	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
KIRC	OS	Median	II,III,IV	0.182	0.696	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NR1I3–LUAD (OS)

Open the LUAD breakdown →